Oxaliplatin (OX) and gemcitabine (GEM) are both drugs with proven clinical activity in various tumor types, have no overlapping toxic side effects and are different with respect to cellular metabolism. Therefore, we performed an in vivo study to determine the efficacy of the combination of these two drugs to optimize the scheduling of both substances using pancreatic ductal adenocarcinoma PAN-02, subcutaneously growing in C57Bl mice. A total of 164 mice were used for cytotoxicity and antitumor studies. The combination therapy resulted in better results than those observed when the drugs were administered individually. GEM (58 mg/kg) and OX (1.0 mg/kg) achieved a 52% reduction in tumor size on day 28 after transplantation and a T/C value of 168% when the intermittent treatment schedule on days 1, 4 and 7 after inoculation was used. This treatment schedule was superior to other therapeutic schedules, producing a synergistic antitumor effect much higher than the one expected by the simple addition of the effects by OX and GEM acting independently.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000100513 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long afterglow hybrid nanoplatform for integrated NIR-Ⅱ imaging diagnosis and triple-synergistic treatment of choroidal melanoma.
Talanta
December 2024
The Key Laboratory of Nonferrous Metal Chemistry and Resources Utilization of Gansu Province and State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, 730000, PR China. Electronic address:
The key to the treatment of choroidal melanoma (CM) is to improve diagnostic efficiency and find a high-performance treatment to replace the traditional treatment of radiotherapy and enucleation. In this paper, for the first time, long afterglow luminescence material was applied to the integrated diagnosis and treatment of eyes, with its unique advantages in photoluminescence and afterglow luminescence to solve the bottleneck problem of real-time irradiation required for photothermal and photodynamic therapy (PTT and PDT). Based on the excellent photoluminescence and afterglow properties of ZnGaGeO:CrYbEr (ZGGO) nanoparticles, a nanoplatform ZGGO@Au@UiO-66@ZnPc:Dox-FA (GAUZD-FA) for NIR-Ⅱ imaging and triple-synergistic therapy (PTT, PDT and sustained-release drug) was constructed.
View Article and Find Full Text PDFA KIF20A-based thermosensitive hydrogel vaccine effectively potentiates immune checkpoint blockade therapy for hepatocellular carcinoma.
NPJ Vaccines
January 2025
First Department of Hepatobiliary Surgery, General Surgery Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Hepatocellular carcinoma (HCC) is a highly prevalent malignancy with limited treatment efficacy despite advances in immune checkpoint blockade (ICB) therapy. The inherently weak immune responses in HCC necessitate novel strategies to improve anti-tumor immunity and synergize with ICB therapy. Kinesin family member 20A (KIF20A) is a tumor-associated antigen (TAA) overexpressed in HCC, and it could be a promising target for vaccine development.
View Article and Find Full Text PDFDual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study.
Cancer Immunol Immunother
January 2025
Department of Oncology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi Province, China.
The combined use of tocilizumab (TCZ) and immune checkpoint inhibitors (ICIs) in cancer treatment is gaining attention, but preclinical studies are lacking. Our study aims to investigate the synergistic anti-tumor effect of TCZ combined with ICIs and its role in treating immune-related adverse events (irAEs). The clinical significance of high interleukin-6 (IL-6) expression in tumor patients was analyzed from the Cancer Genome Atlas (TCGA) database.
View Article and Find Full Text PDFCircRNA-loaded DC vaccine in combination with low-dose gemcitabine induced potent anti-tumor immunity in pancreatic cancer model.
Cancer Immunol Immunother
January 2025
National Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun, China.
Although promising, dendritic cell (DC) vaccines may not suffice to fully inhibit tumor progression alone, mainly due to the short expression time of the antigen in DC vaccines, immunosuppressive tumor microenvironment, and tumor antigenic modulation. Overcoming the limitations of DC vaccines is expected to further enhance their anti-tumor effects. In this study, we constructed a circRNA-loaded DC vaccine utilizing the inherent stability of circular RNA to enhance the expression level and duration of the antigen within the DC vaccine.
View Article and Find Full Text PDFThermosensitive liposome-encapsulated gold nanocages for photothermal-modulated drug release and synergistic photothermal therapy.
J Mater Chem B
January 2025
College of Chemistry and Materials Science, Chemical Biology Key Laboratory of Hebei Province, Hebei Research Center of the Basic Discipline of Synthetic Chemistry, Hebei University, Baoding, 071002, P. R. China.
Delivery nanosystems have been widely developed to improve the efficacy of chemotherapy. However, their performance regarding the non-specific leakage of drugs remained unsatisfactory. Herein, gold nanocages (AuNCs) were used as carriers and thermo-sensitive liposome (TSL) as a protective shell to design a camptothecin (CPT)-loaded delivery nanosystem (AuNCs/CPT@TSL) for photothermal-modulated drug release.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!